CN111065390A - Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途 - Google Patents
Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途 Download PDFInfo
- Publication number
- CN111065390A CN111065390A CN201880059072.XA CN201880059072A CN111065390A CN 111065390 A CN111065390 A CN 111065390A CN 201880059072 A CN201880059072 A CN 201880059072A CN 111065390 A CN111065390 A CN 111065390A
- Authority
- CN
- China
- Prior art keywords
- groups
- pain
- group
- cycloalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
KOR激动剂与MOR激动剂联合在制备治疗疼痛的药物中的用途。所述KOR激动剂选自如通式(I)所示化合物,所述MOR激动剂选自如通式(II)所示化合物,其中通式(I)、(II)的各取代基与说明书中的定义相同。
Description
PCT国内申请,说明书已公开。
Claims (14)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711272869 | 2017-12-06 | ||
CN2017112728691 | 2017-12-06 | ||
PCT/CN2018/119313 WO2019109937A1 (zh) | 2017-12-06 | 2018-12-05 | Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111065390A true CN111065390A (zh) | 2020-04-24 |
CN111065390B CN111065390B (zh) | 2023-01-24 |
Family
ID=66751289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880059072.XA Active CN111065390B (zh) | 2017-12-06 | 2018-12-05 | Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11471503B2 (zh) |
EP (1) | EP3714882A4 (zh) |
JP (1) | JP2021505547A (zh) |
KR (1) | KR20200096787A (zh) |
CN (1) | CN111065390B (zh) |
AU (1) | AU2018380173A1 (zh) |
BR (1) | BR112020010429A2 (zh) |
CA (1) | CA3083028A1 (zh) |
MX (1) | MX2020005660A (zh) |
TW (1) | TW201924681A (zh) |
WO (1) | WO2019109937A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109982699A (zh) * | 2017-04-14 | 2019-07-05 | 江苏恒瑞医药股份有限公司 | 一种mor激动剂与kor激动剂的药物组合物及其用途 |
CN112694485A (zh) * | 2020-09-10 | 2021-04-23 | 四川海品信医药科技有限公司 | 一种阿片受体激动剂噻吩类化合物及其制备方法 |
CN114269738A (zh) * | 2020-08-10 | 2022-04-01 | 成都苑东生物制药股份有限公司 | 一种mor受体激动剂化合物、制备方法及其用途 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020147848A1 (zh) * | 2019-01-17 | 2020-07-23 | 上海海雁医药科技有限公司 | 三环取代的氧杂螺环衍生物、其制法与医药上的用途 |
CN113493490B (zh) * | 2020-04-03 | 2024-03-12 | 成都诺和晟泰生物科技有限公司 | 一种合成肽酰胺类化合物及其在医药领域的用途 |
JP2023536221A (ja) | 2020-06-25 | 2023-08-24 | ヒューマンウェル ファーマシューティカル ユーエス | 医学的障害の治療のためのペプチド |
CN113995733B (zh) * | 2021-09-18 | 2023-08-22 | 中国人民解放军军事科学院军事医学研究院 | 一种噻吩诺啡缓释药物组合物及其制备方法和其用途 |
CN115317453A (zh) * | 2022-09-01 | 2022-11-11 | 广东嘉博制药有限公司 | 一种缓释微球制剂及其制备方法与用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201601743A (zh) * | 2013-10-28 | 2016-01-16 | 卡拉治療股份有限公司 | 外周kappa鴉片受體促進劑用於製備預防、抑制或治療噁心及嘔吐之藥物的用途 |
WO2017063509A1 (zh) * | 2015-10-15 | 2017-04-20 | 江苏恒瑞医药股份有限公司 | 氧杂螺环类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007317817B2 (en) * | 2006-11-10 | 2012-09-20 | Cara Therapeutics, Inc. | Synthetic peptide amides |
US7842662B2 (en) * | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
US8906859B2 (en) | 2006-11-10 | 2014-12-09 | Cera Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
ES2857549T3 (es) | 2011-03-23 | 2021-09-29 | Trevena Inc | Ligandos de receptores de opioides y métodos para utilizar y obtener los mismos |
DK2822928T3 (en) | 2012-03-05 | 2019-03-11 | Dr Reddys Laboratories Ltd | SUBSTITUTED HETEROCYCLIC ACETAMIDS AS CAPE-OPIOID RECEPTOR (CHOR) AGONISTS |
US20180028594A1 (en) | 2014-11-05 | 2018-02-01 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for hard tissue pain |
UA123737C2 (uk) * | 2016-06-07 | 2021-05-26 | Джянгсу Хенгруй Медісін Ко., Лтд. | Похідне фенілпропанаміду та спосіб отримання, та його фармацевтичне застосування |
CN108883185B (zh) | 2016-12-06 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途 |
EP3610874A4 (en) * | 2017-04-14 | 2021-01-06 | Jiangsu Hengrui Medicine Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING A MOR AGONIST AND A KOR AGONIST, AND ITS USES |
-
2018
- 2018-12-05 AU AU2018380173A patent/AU2018380173A1/en not_active Abandoned
- 2018-12-05 CN CN201880059072.XA patent/CN111065390B/zh active Active
- 2018-12-05 CA CA3083028A patent/CA3083028A1/en active Pending
- 2018-12-05 JP JP2020529356A patent/JP2021505547A/ja active Pending
- 2018-12-05 BR BR112020010429-9A patent/BR112020010429A2/pt not_active Application Discontinuation
- 2018-12-05 KR KR1020207018160A patent/KR20200096787A/ko active Search and Examination
- 2018-12-05 MX MX2020005660A patent/MX2020005660A/es unknown
- 2018-12-05 EP EP18885338.6A patent/EP3714882A4/en not_active Withdrawn
- 2018-12-05 TW TW107143659A patent/TW201924681A/zh unknown
- 2018-12-05 WO PCT/CN2018/119313 patent/WO2019109937A1/zh active Application Filing
- 2018-12-05 US US16/767,523 patent/US11471503B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201601743A (zh) * | 2013-10-28 | 2016-01-16 | 卡拉治療股份有限公司 | 外周kappa鴉片受體促進劑用於製備預防、抑制或治療噁心及嘔吐之藥物的用途 |
WO2017063509A1 (zh) * | 2015-10-15 | 2017-04-20 | 江苏恒瑞医药股份有限公司 | 氧杂螺环类衍生物、其制备方法及其在医药上的应用 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109982699A (zh) * | 2017-04-14 | 2019-07-05 | 江苏恒瑞医药股份有限公司 | 一种mor激动剂与kor激动剂的药物组合物及其用途 |
CN114269738A (zh) * | 2020-08-10 | 2022-04-01 | 成都苑东生物制药股份有限公司 | 一种mor受体激动剂化合物、制备方法及其用途 |
CN114269738B (zh) * | 2020-08-10 | 2023-09-29 | 成都苑东生物制药股份有限公司 | 一种mor受体激动剂化合物、制备方法及其用途 |
CN112694485A (zh) * | 2020-09-10 | 2021-04-23 | 四川海品信医药科技有限公司 | 一种阿片受体激动剂噻吩类化合物及其制备方法 |
CN112694485B (zh) * | 2020-09-10 | 2023-04-07 | 四川海品信医药科技有限公司 | 一种阿片受体激动剂噻吩类化合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2021505547A (ja) | 2021-02-18 |
EP3714882A1 (en) | 2020-09-30 |
US20200368309A1 (en) | 2020-11-26 |
RU2020115687A (ru) | 2022-01-11 |
US11471503B2 (en) | 2022-10-18 |
MX2020005660A (es) | 2020-08-20 |
EP3714882A4 (en) | 2021-09-01 |
BR112020010429A2 (pt) | 2020-11-24 |
KR20200096787A (ko) | 2020-08-13 |
AU2018380173A1 (en) | 2020-05-21 |
WO2019109937A1 (zh) | 2019-06-13 |
RU2020115687A3 (zh) | 2022-01-31 |
CN111065390B (zh) | 2023-01-24 |
TW201924681A (zh) | 2019-07-01 |
CA3083028A1 (en) | 2019-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111065390B (zh) | Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途 | |
EP3610874A1 (en) | Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof | |
JP6147799B2 (ja) | Parpインヒビターとの組合せ療法 | |
JP2018162260A (ja) | カンナビノイド受容体モジュレーター | |
TW200831086A (en) | Spirocyclic Azetidinone Compounds and methods of use thereof | |
CN101516840A (zh) | 取代的n-酰基苯胺及其应用方法 | |
TW200810752A (en) | Modulators of muscarinic receptors | |
WO2006118307A1 (ja) | 疼痛治療薬 | |
KR101471585B1 (ko) | 트라마돌 및 콕시브의 공결정 | |
JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
JPWO2007020935A1 (ja) | P2y12受容体および/またはp2y14受容体ブロッカーを含有してなる疼痛治療剤 | |
JP2021513512A (ja) | 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸 | |
US20210046082A1 (en) | Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use | |
MXPA04006777A (es) | Ligandos de receptor de histamina-3 para condiciones diabeticas. | |
RU2776842C2 (ru) | Применение агониста kor в комбинации с агонистом mor для получения лекарственного средства для лечения боли | |
WO2022246025A1 (en) | Inhibitors and degraders of pip4k protein | |
JP4428481B2 (ja) | 神経因性疼痛治療剤 | |
TWI847445B (zh) | 一種噠嗪類化合物、其藥物組合物及應用 | |
JP2019509321A (ja) | 疼痛を処置するための組み合わせ | |
CN107200725B (zh) | 稠杂环类衍生物、其制备方法及其在医药上的应用 | |
JP2006306738A (ja) | 神経因性疼痛治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40025414 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |